Avid Bioservices Inc (CDMO)

[hutschi]

TUMOR IMMUNITY United States Patent Application 20170224793

Inventors:

Dranoff, Glenn (Lexington, MA, US)
Jinushi, Masahisa (Tokyo, JP)

Assignee:

Dana-Farber Cancer Institute, Inc. (Boston, MA, US)


Publication Date:

08/10/2017


Filing Date:

09/26/2016

A method of treating a cancer or cancer symptom in a subject, the method comprising administering to the subject an effective amount of one or more tumor cell antigens that elicit an immune response against a tumor and an MFG-E8, wherein the MFG-E8 inhibitor is selected from the group consisting of an anti-MFG-E8 antibody, an anti-phosphatidyl serine antibody, an MFG-E8 polypeptide that lacks the ability to bind integrins; and an MFG-E8 polypeptide that lacks the ability to bind phosphatidyl serine.

Antibodies

An MFG-E8 inhibitor can be an antibody. In one embodiment, the antibody can be an anti-MFG-E8 antibody. In another embodiment, the antibody can be an anti-PS antibody. Anti-PS antibodies and ligands for binding PS are described in U.S. Pat. Nos. 6,406,693, 6,818,213, 6,312,694, and 6,783,760 and in Beck et al. 2006 Int J Cancer 118:2639-43. Anti-PS antibodies e.g., Bavituximab (Peregrine Pharmaceuticals), are also described on the National Cancer Institute's clinical trials database at http//canger.gov/clinical trials. In another embodiment, the antibody can be an antibody that specifically recognizes and blocks the activity of a molecule that functions in the uptake of PS. Examples of PS-uptake targets include Del-1 (see for example, without limitation, NP_005702, GI:31317224), Gas6 (see for example, without limitation, NP_000811, GI:4557617), Mer (see for example, without limitation, NP_006334, GI:66932918) and members of the Tyro family (see for example, without limitation, NP_006284, GI:27597078.) As used herein, useful antibodies can include: monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, bifunctional/bispecific antibodies, humanized antibodies, human antibodies, and complementary determining region (CDR)-grafted antibodies, that are specific for the target protein or fragments thereof, and also include antibody fragments, including Fab, Fab', F(ab')2, scFv, Fv, camelbodies, or microantibodies.

http://www.freepatentsonline.com/y2017/0224793.html